Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

All India Institute of Medical Sciences (AIIMS) and the Indian Space Research Organisation (ISRO) signed a Memorandum of Understanding (MoU) on Monday to collaborate on advancing research in space medicine.

The MoU was signed between M Srinivas, Director (AIIMS), New Delhi and Dinesh Kumar Singh, Director, Human Space Flight Centre (HSFC), ISRO. The event brought together senior leadership from AIIMS and ISRO, including ISRO Chairman V Narayanan and Secretary, Department of Space, as well as Deans, Heads of Departments, faculty members, and studies from AIIMS New Delhi.

Also Read: Is There A Link Between Your Kidney Health And Other Chronic Diseases? Study Says Yes

As per the news agency Asian News International (ANI), a press release of the collaboration noted for a cooperative framework for ground-based and space-based research in Space Medicine. The press release also noted that the research will cover areas like human physiology, cardiovascular and autonomic regulation, musculoskeletal health in microgravity, microbiome and immunology, genomics and biomarkers and behavioral health.

“This MoU will give us the escape velocity to venture together into the field of space medicine. Collaborative research between AIIMS and ISRO will benefit patients, the nation, and ultimately humankind. As India moves toward Viksit Bharat by 2047, we hope to emerge as a Vishwaguru in space medicine as well,” said Prof M Srinivas, Director, AIIMS, New Delhi.

Chairman of ISRO Dr V Narayanan and Secretary, Department of Space also highlighted India’s remarkable journey in space programme. He noted how India evolved from the time when rockets and equipment were transported on bicycles and bullock carts to today, where it is going to be leading medical and research institutions like AIIMS to strengthen India’s human spaceflight capabilities.

The programme also featured a presentation on AIIMS New Delhi’s ongoing work in space medicine research, delivered by Prof. KK Deepak, former Head of the Department of Physiology. The event was attended by Heads of Departments and faculty members from across AIIMS New Delhi, along with representatives from the Resident Doctors Association (RDA), the AIIMS Student Association (ASA), and the Society of Young Scientists (SYS).

The collaboration represents an important step toward enhancing India’s capabilities in human spaceflight and biomedical research. It also aligns with the country’s broader scientific ambitions as India moves toward its centenary in 2047 and the vision of Viksit Bharat.

Read: Sunita Williams Retires After 27 Years: Health Challenges She Faced After Spending 600+ Days in Space

What Do We Already Know About Space Medicine?

As per a 2017 study in the British Journal of Anaesthesia, space medicine is fundamental to the human exploration of space. It supports survival, function and performance in this challenging as potentially lethal environment. It is international, intercultural and interdisciplinary, operating at the boundaries of exploration, science, technology and medicine.

Space medicine specialists play a crucial role in safeguarding astronauts and other spaceflight participants. Known as “flight surgeons,” they help develop strategies to protect the health, safety, and performance of space travellers in the extreme conditions of space. Their responsibilities span every stage of a mission — from selection and training to in-flight care, post-mission rehabilitation, and monitoring long-term health effects.

With inputs from ANI

Sick days are again piling up with a respiratory disease, not COVID-19 or the flu. This disease is most likely the one Americans have not heard of. This is HMPV or human metapneumovirus. Doctors have asked people to stay vigilant as seasonal flu virus could lead to pneumonia and bronchitis, and it is spreading in California wastewater and around the country. However, as per public health officials, there is nothing to get worried at this point.

Also Read: Is There A Link Between Your Kidney Health And Other Chronic Diseases? Study Says Yes

As per the public database WasterwaterScan Dashboard, high levels of HMPV were detected across Northern California cities. The highest levels were reported in Redwood City, whereas elevated levels were found in San Francisco Bay Area and Napa's Wine Country. What's more dangerous is that this virus is without a vaccine.

The good news is that in other parts of country HMPV remains lower. However, the Centers for Disease Control and Prevention (CDC) noted that data from October 2025 shows the cases are trending up, especially during winter and spring.

Dr. Matthew Binnicker, director of the Clinical Virology Laboratory at Mayo Clinic, as reported by The Independent said, "In the late winter, early spring, it can account for five percent to 10 percent of all the respiratory infections that we diagnose in the United States. So it's definitely out there." Experts explain that other viruses like HMPV or influenza get a chance when COVID is quieter.

Read: HMPV Virus Cases Surging In California, New Jersey: Is It Dangerous?

Virus Without A Vaccine: What Is HMPV?

HMPV was first discovered in 2001 and is part of the Pneumoviridae family along with the Respiratory syncytial virus (RSV).

HMPV most likely spreads from an infected person to others through:

• the air by coughing and sneezing
• close personal contact, such as touching or shaking hands
• touching objects or surfaces that have the viruses on them, then touching the mouth, nose, or eyes

In the US, HMPV circulates in predictable patterns each year, typically beginning in winter and lasting through spring.

The usually self-limiting and mild symptoms typically last 4 to 5 days. These include:

• cough
• fever
• nasal congestion
• shortness of breath

People at risk include:

• elderly people
• children
• people with comorbidities

"The HMPV is not deadly, and there is no evidence of mortality or a severe transmission rate," former Indian Council of Medical Research (ICMR) scientist, Dr. Raman Gangakhedkar, told IANS, during the virus's outbreak in India in 2025.

“The virus may cause pneumonitis-like illness, but the mortality rates are almost unknown so far. HMPV has a global prevalence of about 4 per cent,” he added.

While no vaccine or treatment can prevent HMPV infection, to avoid the infection, individuals must:

Practice good hygiene and cover your mouth and nose with a tissue when coughing or sneezing, or use your elbow, not your hands, for it. And wash your hands properly, especially in healthcare settings.

Why Are People Hearing About The Virus Without Vaccine Now?

The reason people have not heard about it before is because its symptoms are nearly indistinguishable from other respiratory infections, so often it could go undiagnosed. Furthermore, earlier the COVID cases and influenza cases sparked up, which deviated the attention from HMPV. Now, with the season gone, and increased awareness around respiratory illnesses, greater attention to viruses like HMPV is also paid.

One in seven Indians, or over 14 percent of the population, suffers from some form of mental health disorder. Amid an increasing treatment gap -- up to 90 percent -- seen in several states, especially in North India, the government today reiterated the plan of launching a second National Institute of Mental Health and Neurosciences (NIMHANS) in the northern states.

NIMHANS-2 was first announced by Finance Minister Nirmala Sitharaman during the Union Budget 2026-27, to deliver specialized care for mental health and neurological disorders in north India.

Health experts and policymakers, as part of the government-led Post-Budget Webinar series, highlighted the growing burden of mental and neurological disorders in India and also stressed the urgent need to strengthen institutional capacity to meet emerging healthcare demands.

"One in seven Indians is affected by mental health disorders, while several states continue to face a treatment gap ranging from 70 to 90 percent," the experts said.

Noting that Non-Communicable Diseases (NCDs) account for over 60 percent of deaths in the country, they added that "neurological and mental health conditions are among the leading contributors to disability-adjusted life years (DALYs)," among the citizens.

Need For Tertiary Neuro-psychiatric Care

To address these, the experts called for ramping up tertiary mental health institutions and expanding specialized services.

The session, moderated by Vijay Nehra, Joint Secretary, Ministry of Health and Family Welfare, highlighted that North India currently lacks adequate tertiary neuro-psychiatric care facilities. These include areas such as:

• advanced neuroimaging,
• neurocritical care,
• specialized neurological services

Further, making a virtual address at the Post-Budget Webinar, Union Health Minister JP Nadda also highlighted the government’s focus on strengthening mental healthcare services in the country.

"NIMHANS-2 will be established in North India to expand advanced clinical care, training, and research," Nadda said.

"In addition, the Central Institute of Psychiatry, Ranchi, and the Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur, will be upgraded as regional apex institutions to strengthen mental healthcare services in the eastern and north-eastern regions," he added.

Meanwhile, the experts also stressed the need to improve services in underserved and geographically remote regions, including the northeastern states, through better infrastructure, capacity building, and targeted deployment of trained mental health professionals.

They also discussed strategies for expanding advanced neuro-psychiatric care and reinforcing India’s overall mental healthcare ecosystem. They proposed:

• Adopting a hub-and-spoke model supported by digital health platforms

This would allow tertiary institutions and centers of excellence to provide technical guidance, specialist consultations, and clinical support to district hospitals and community-level health facilities.

"Such a model would strengthen referral pathways and ensure that specialized mental health services are accessible to people even in remote and rural areas," the experts said.

• Integrating services under Tele-MANAS

Both existing and upcoming campuses of NIMHANS must be integrated , as this will enable a robust nationwide tele-mental health network that ensures

• timely counselling,
• psychological support,
• specialist consultations

• Digital follow-up systems

The experts called for the seamless integration of healthcare facilities, aligned with the vision of the Ayushman Bharat Digital Mission and the ABHA ID ecosystem. This, they said, will

• enable continuity of care,
• Improve monitoring of patients,
• Lead to better clinical outcomes

• A national Brain-Mind Cloud Network

The Network proposed under the National Health Mission would connect premier institutions such as All India Institute of Medical Sciences (AIIMS), state medical colleges, and primary healthcare centers through a digitally integrated platform.

It could also facilitate

• unified mental health records,
• AI-based screening tools,
• data-driven clinical decision support systems,
• tele-neuro-psychiatric hubs at regional centers.